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Summary. The ether lipid miltefosine (hexadecylphos- 
phocholine) was orally given to patients with various tu- 
mours in a d0se-finding study. All patients initially re- 
ceived a daily total dose of 100 mg, which in the absence 
of side-effects was increased to 150 mg and further to 
200 mg. A total of 54 patients were entered and were 
evaluable for gastrointestinal toxicity. Nausea and vom- 
iting were found to be dose-limiting; 22% of patients 
ultimately tolerated a dose of 100 mg, 59% tolerated a
dose of 150 mg and 19% tolerated a dose of 200 mg. In 
addition 30% of patients developed renal dysfunction, 
which was thought to be related to the drug. No other 
toxities were observed. For further phase I I  studies it is 
recommended that one starts with a dose of 150 mg daily, 
divided over three administrations. 
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Introduction 
Ether lipids have been the subject of laboratory anti- 
cancer research for several years. Only recently some of 
these drugs were introduced in clinical trials, still mainly 
restricted to phase I studies. 
Miltefosine (hexadecylphosphocholine) was one of 
the first ether lipids to enter clinical studies (Unger et al. 
1989 a, 1990). The drug is a synthetic phospholipid eriv- 
ative with remote similarity to the major constituent of 
the cell membrane, lecithin. Therefore, although the de- 
tailed mode of action is still unknown, selective interfer- 
ence avith membrane functions is presumed. 
In vitro the drug is active in the L1210, HL-60, U937 
Raji and K562 leukaemia cell lines (Unger et al. 1989 b). 
Activity was also found in the KB cell line (Fleer et al. 
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1987). Owing to haemolytic effects an i.v. formulation 
was difficult; however, an oral formulation became avail- 
able. By oral application the drug was active in vivo in di- 
methylbenz[a]anthracene-induced breast cancers in mice 
(Unger et al. 1989b; Eibl et al. 1988) and mammary hu- 
man tumour xenografts (Scherf et al. 1987), and had a 
high bioavailability (Unger et al. 1989 b). 
Distribution studies showed a high accumulation in 
the kidneys, lung and liver (Unger et al. 1989 b; Breiser et 
al. 1987). In a phase I study in 22 patients the dose-limit- 
ing toxicities of miltefosine were nausea and vomiting, 
which could be reduced by splitting the daily dose into 
multiple administrations. No other toxicities were noted. 
The dose recommended for phase II studies was 150 mg/ 
day. However, because the phase I data were scanty, it 
was decided that a dose-finding study within a large 
phase II study programme should be performed. 
Materials and methods 
Patients with metastatic histologically confirmed colorectal, non- 
small-cell lung or squamous-cell head and neck cancer were eligible 
for the (dose-finding) study. For eolorectal and head and neck 
cancer one prior form of chemotherapy was permitted. Prior chemo- 
therapy was not allowed for patients with non-small-cell lung 
cancer. Patients had to have a WHO performance score of 2 or less 
and normal serum creatinine and bilirubin. There were no age limits. 
Verbal informed consent was required. 
Miltefosine (hexadecylphosphocholine, D 18506) was supplied 
by ASTA Medica AG in capsules containing 50 mg active drug/ 
capsule. Treatment consisted of miltefosine 50 mg orally twice daily 
after meals in the first week. In the absence of side-effects this dose 
was increased to three times daily in the second week. In the case of 
a total absence of side-effects a further escalation to four times daily 
was performed inweek 3 or 4. In the case of nausea nd/or vomiting, 
adequate oral antiemetics were given; if these were ineffective a dose 
reduction by one step was allowed. Patients not tolerating 50 mg 
twice daily were taken off study. The highest tolerated ose per pa- 
tient was given until tumour progression. 
Prior to treatment, baseline haematology and chemistry data 
were obtained. For the first 8 weeks, weekly haemoglobin, white 
blood cells and platelets were determined; thereafter these were re- 
corded every 4 weeks. Every 4 weeks a complete cheek of serum 
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chemistry, including serum creatinine, sodium, potassium, calcium, 
bilirubin, alkaline phosphatase and aspartate and alanine amino- 
transferases, was performed. 
Response and toxicity were evaluated according to WHO crite- 
ria. For nausea/vomiting theworst grade during the week was re- 
corded, so if a patient vomited once during a week this was consid- 
ered to be grade 2. 
Table 1. Percentage nausea/vomiting per dose level over the total 
length of treatment 
Daily dose Total length of Patients experiencing (%) 
(mg) treatment to WHO level: 
(weeks) 
0 1 2 
Results 
100 94 59 34 7 
150 188 46 27 27 
200 33 61 27 12 
A total of 54 patients entered the study, 34 men and 20 
women, with a median age of 58 years (range 32-79) and 
a median WHO performance score of 1 (range 0-2). 31 
patients had colorectal cancer, 13 had non-small-cell lung 
cancer and 10 had squamous-cell head and neck cancer. 
Seven patients had had prior chemotherapy consisting of 
5-fluorouracil (3 patients), methotrexate (3 patients) and/ 
or cisplatin (1 patient), or prior immunotherapy with in- 
terleukin-2 (2 patients). 
A total of 315 weeks of treatment with miltefosine 
were evaluated. The median duration of treatment was 6 
weeks (range 2-8 + weeks). All patients tarted at a daily 
dose of 100 mg miltefosine and in 51 (94%) the dose 
could be increased to 150 rag. A further dose escalation 
to 200 mg daily was performed in 11 patients (20%). 
Nausea and/or vomiting were found to be dose-limiting 
and occurred in 48% of the treatment weeks; 29% 
grade 1 (WHO) and 19% grade 2. 
The percentage of nausea/vomiting analysed per dose 
level over the total number of treatment weeks is given in 
Table 1. 
The dose tolerated until the end of treatment was 
100 mg in 12 patients (22%), 150 mg in 32 patients (59%) 
and 200 mg in 10 patients (19%). In most patients the 
worst grade of nausea/vomiting per dose level was ob- 
served in the first week of treatment at that dose level. 
However, in some patients nausea/vomiting did not oc- 
cur until some weeks after treatment had begun. 
Most standard antiemetics (including 5HT3 antago- 
nists) were ineffective in preventing nausea/vomiting. 
The least emetogenic effect was obtained if miltefosine 
was taken immediately after meals, with domperidon 
taken 0.5 h before the meals at a dose of 20 mg. 
The only other side-effect observed was renal toxicity. 
Eight patients could not be evaluated in this respect be- 
cause there was no follow-up creatinine determination. 
Renal toxicity consisted of an increase in serum creati- 
nine level and occurred in 14 (30%) out of 46 evaluable 
patients. In 12 patients it was grade 1 (26%) and in 2 it 
was grade 2 (4%). In 3 patients treatment had to be stop- 
ped because of the renal side-effects; in 2, serum creati- 
nine normalized after the drug was discontinued. In one 
patient we were unable to observe recovery from this 
side-effect because in the meantime this patient died from 
pneumonia. At autopsy, renal changes consisted of inter- 
ruptions of the epithelial lining of the descending tubules 
caused by plasmacellular infiltrates. 
In 3 patients treatment was stopped because of disease 
progression at the time that renal toxicity was found. In 
these patients renal function fully recovered. In 2 of the 
other remaining 6 patients renal dysfunction ormalized 
notwithstanding the continuation of full-dose treatment. 
In the other 4 patients erum creatinine levels reached a
plateau during miltefosine therapy and returned to nor- 
mal after cessation. The time to recovery from renal tox- 
icity varied from 2 to 30 weeks (median 4). Five patients 
had not experienced nausea/vomiting at all when renal 
toxicity occurred; 6 patients experienced nausea and 3 
had vomited sporadically. The latter 9 patients denied in- 
adequate fluid intake in the weeks preceding the occur- 
rence of renal toxicity. 
There was no myelosuppression, no hair loss and no 
other sign of organ toxicity. 
Discussion 
Our dose-finding study confirmed by and large the dose- 
limiting gastrointestinal toxicity observed in the previous 
phase I studies (Unger et al. 1990). Nausea and vomiting 
appear to be dose-dependent as far as the final tolerance 
of patients is concerned. However, our data indicate that 
a patient-guided dose escalation is feasible without the 
frequency of this side-effect being increased. 
In addition we report he development ofreversible re- 
nal dysfunction in 30% of patients, which is probably 
caused by an intrinsic renal esion as demonstrated in one 
autopsy case. The percentage of renal toxicity may be 
somewhat overestimated because of the possible ffect of 
a coinciding decrease in the effective circulating volume 
related to inadequate fluid intake resulting from nausea/ 
vomiting. 
On the basis of animal data, renal toxicity was not an 
unexpected finding. Although renal toxicity itself was not 
seen in these studies (Unger et al. 1989 b; Eibl et al. 1988), 
a high accumulation of the drug in the kidneys was re- 
ported (Unger et al. 1989b; Breiser et al. 1987). As this 
side-effect was first seen after a median of 5 weeks of 
treatment (range 3-8), it is difficult to deduce a possible 
relationship to the daily dose. Although it cannot be com- 
pletely excluded, there was no obvious relationship to cu- 
mulative dose. We did not find any relationship between 
the renal toxicity and other clinical parameters. 
Oral miltefosine completely lacked any other toxicity. 
As was reported earlier, we only observed two tumour e- 
gressions in colorectal cancer patients (Planting et al. 
1990). Oral miltefosine can be given safely to patients at 
a dose of 150 rag/day, divided over three doses. Prophy- 
lactic use of oral domperidon is recommended. Careful 
monitoring of serum creatinine is also advisable. 
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